What is Oruka Therapeutics, Inc.'s pre-tax stock-based compensation cost?

Oruka Therapeutics, Inc. (ORKA) reported pre-tax stock-based compensation cost of $6.97M in Q1 2026.

How has Oruka Therapeutics, Inc.'s pre-tax stock-based compensation cost changed year-over-year?

Oruka Therapeutics, Inc.'s pre-tax stock-based compensation cost increased by 42.7% year-over-year, from $4.88M to $6.97M.

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Market cap$5.03B+533%

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

What is Oruka Therapeutics, Inc.'s pre-tax stock-based compensation cost?: Oruka Therapeutics, Inc. (ORKA) reported pre-tax stock-based compensation cost of $6.97M in Q1 2026.
How has Oruka Therapeutics, Inc.'s pre-tax stock-based compensation cost changed year-over-year?: Oruka Therapeutics, Inc.'s pre-tax stock-based compensation cost increased by 42.7% year-over-year, from $4.88M to $6.97M.